Over ten years overall survival in glioblastoma: A different disease?

Marton, Elisabetta; Giordan, Enrico; Siddi, Francesca; Curzi, Christian; Canova, Giuseppe; Scarpa, Bruno; Guerriero, Angela; Rossi, Sabrina; Avella, Domenico D’; Longatti, Pierluigi; Feletti, Alberto

doi:10.1016/j.jns.2019.116518

Cited by 21 publications

(32 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median relative survival among GBM patients is 15 months and the two-year relative survival is 25% [ 6 ]. Only 0.71% of patients survive more than 10 years, [ 9 ] and 20 years of survival, as in this case, is rare and was reported in only a few cases [ 9 - 12 ].…”

Section: Discussionmentioning

confidence: 90%

Twenty Years After Glioblastoma Multiforme Diagnosis: A Case of Long-Term Survival

Rabab’h¹,

Al-Ramadan²,

Shah³

et al. 2021

Cureus

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is an aggressive tumor that has a poor prognosis with a median survival of 15 months with treatment and 3-4 months without treatment. Subsets of patients are found to survive longer than two years, some survivors lived more than 10 years, and rare cases survived 20 years or more with treatment. Better prognosis has been found to be associated with many factors. Some of these factors are related to patients' characteristics, biological factors that impact tumor aggressiveness, and/or factors associated with treatment. However, the exact contribution for extended survival is still not known. Finding the factors that have a strong impact on the long survival is of high importance and can help give hope to better treat glioblastoma cases. In this report, we present a case of a glioblastoma patient who was diagnosed at the age of 47 years with more than 20-year survival. We further discuss the suggested factors that may have contributed to a better prognosis with a focus on the possible role of varicella-zoster infection in mediating long-term survival.

show abstract

Section: Discussionmentioning

confidence: 90%

Twenty Years After Glioblastoma Multiforme Diagnosis: A Case of Long-Term Survival

Rabab’h¹,

Al-Ramadan²,

Shah³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…Glioblastomas (GBM) is the most invasive and prevalent types of glioma with extremely poor prognosis and limited treatment options (Rebhandl et al, 2015). In recent years, tremendous articles reported the molecular characterization of GBM, make us better understanding of how to use the key molecules to predict the OS for glioma patients (Colaprico et al, 2016;Holdhoff, 2018;Higashijima and Kanki, 2019;Marton et al, 2019). However, most of the published articles were based on single platform analysis, which is hard to explain why the similar molecular pattern may induce diverse prognosis in GBM patients sometimes.…”

Section: Discussionmentioning

confidence: 99%

“…Gliomas are most common malignant brain tumors which derive from neuroepithelial cells (Rivera et al, 2008). Most patients underwent tumor resection surgery with standard follow-up chemotherapy/radiotherapy, and based on molecular neuropathology diagnosis, they may survive from months to decades (median survival from 1 year to 15 years) (Marton et al, 2019). High-grade gliomas' recurrence was due to their invasive nature.…”

Section: Introductionmentioning

confidence: 99%

“…High-grade gliomas' recurrence was due to their invasive nature. Recent studies on molecular pathology of glioma has outlined some valuable prognosis biomarkers such as IDH1, 1q-19p co-deletion, h3k27, TERT (Killela et al, 2014;Marton et al, 2019;, but the existed biomarkers still cannot fully predict the overall survival for all glioblastoma patients, such as IDH1 wild-type in WHO grade 2 gliomas or in recurrent gliomas; moreover, we know a little about of the MGMT demethylation status in glioma patients. Unlike many other types of malignant tumor, glioblastoma lacks of effective treatment measures and drug targets (Snape and Warr, 2015;Higashijima and Kanki, 2019;Ruta et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multi-Omics Analysis Reveals Novel Subtypes and Driver Genes in Glioblastoma

et al. 2020

View full text Add to dashboard Cite

Glioblastoma is the most lethal malignant primary brain tumor; nevertheless, there remains a lack of accurate prognostic markers and drug targets. In this study, we analyzed 117 primary glioblastoma patients’ data that contained SNP, DNA copy, DNA methylation, mRNA expression, and clinical information. After the quality of control examination, we conducted the single nucleotide polymorphism (SNP) analysis, copy number variation (CNV) analysis, and infiltrated immune cells estimate. And moreover, by using the cluster of cluster analysis (CoCA) methods, we finally divided these GBM patients into two novel subtypes, HX-1 (Cluster 1) and HX-2 (Cluster 2), which could be co-characterized by 3 methylation variable positions [cg16957313(DUSP1), cg17783509(PHOX2B), cg23432345(HOXA7)] and 15 (PCDH1, CYP27B1, LPIN3, GPR32, BCL6, OR4Q3, MAGI3, SKIV2L, PCSK5, AKAP12, UBE3B, MAP4, TP53BP1, F5, RHOBTB1) gene mutations pattern. Compared to HX-1 subtype, the HX-2 subtype was identified with higher gene co-occurring events, tumor mutation burden (TBM), and poor median overall survival [231.5 days (HX-2) vs. 445 days (HX-1), P-value = 0.00053]. We believe that HX-1 and HX-2 subtypes may make sense as the potential prognostic biomarkers for patients with glioblastoma.

show abstract

“…These authors analyzed 58 patients with glioblastoma and observed a median survival of 19.2 months in patients with methylated MGMT versus 7.6 months in patients with unmethylated MGMT. Similarly, a larger retrospective study including 119 patients analyzed the state of MGMT methylation and survival, among other factors [ 47 ]. The results obtained indicate that patients under 50 years old with methylation of the MGMT promoter are those with the greatest survival.…”

Section: Mechanisms Of Temozolomide Resistancementioning

confidence: 99%

Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications

Ortíz

Perazzoli

Cabeza

et al. 2021

View full text Add to dashboard Cite

: Temozolomide (TMZ), an oral alkylating prodrug which delivers a methyl group to purine bases of DNA (O6- guanine; N7-guanine and N3-adenine), is frequently used together with radiotherapy as part of the first-line treatment of high-grade gliomas. The main advantages are its high oral bioavailability (almost 100% although the concentration found in the cerebrospinal fluid was approximately 20% of the plasma concentration of TMZ), its lipophilic properties, and small size that confer the ability to cross the blood-brain barrier. Furthermore, this agent has demonstrated activity not only in brain tumors but also in a variety of solid tumors. However, conventional therapy using surgery, radiation, and TMZ in glioblastoma results in a median patient survival of 14.6 months. Treatment failure has been associated with the tumor drug resistance. This phenomenon has been linked to the expression of O6-methylguanine-DNA methyltransferase, but the mismatch repair system and the presence of cancer stem-like cells in tumors have also been related to TMZ resistance. The understanding of these mechanisms is essential for the development of new therapeutic strategies in the clinical use of TMZ, including the use of nanomaterial delivery systems and the association with other chemotherapy agents. The aim of this review is to summarize the resistance mechanisms of TMZ and the current advances to improve its clinical use.

show abstract

Over ten years overall survival in glioblastoma: A different disease?

Cited by 21 publications

References 40 publications

Twenty Years After Glioblastoma Multiforme Diagnosis: A Case of Long-Term Survival

Twenty Years After Glioblastoma Multiforme Diagnosis: A Case of Long-Term Survival

Multi-Omics Analysis Reveals Novel Subtypes and Driver Genes in Glioblastoma

Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications

Contact Info

Product

Resources

About